Cobicistat TOS

Phase 3Small molecule

Gilead

Cobicistat TOS is one of 62 small molecule programs targeting HIV-1 infection. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HIV-1 InfectionRecruiting

TenofovirActive, not recruiting

HIV-1 InfectionPhase 3

Recruiting

TenofovirPhase 3

Active, not recruiting

Competition

Competitive Landscape

61 competitors in HIV-1 Infection

#DrugCompanyPhaseTrials

Cabenuva

GSK

Approved

2 2

Epidiolex

Jazz Pharmaceuticals

Approved

1 3

Tybost

Gilead

Approved

1 4

Venclexta

AbbVie

Approved

1 5

Vemlidy

Taxol

Niacor

Renvela

Ziagen

Bayer Aspirin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2/3Active, not recruiting

Tenofovir

NCT02016924

Q1 2034

ApprovedRecruiting

HIV-1 Infection

NCT06337032

Clinical

Trials by Indication[1]

Tenofovir1 trial

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

Active, not recruiting· Gilead logo

Gilead·Phase 2/3·NCT02016924·133 enrolled

HIV-1 infection1 trial

An Open-label, Single-arm Study to Provide Continued Access to Study Drug to Participants Who Have Completed Pediatric Clinical Studies Involving Gilead HIV Treatments

Recruiting· Gilead logo

Gilead·Approved·NCT06337032·350 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Cobicistat TOS. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cobicistat TOS compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cobicistat TOS. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gilead company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Gilead

Cobicistat TOS

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q1 2034

Trials by Indication[1]

Tenofovir1 trial

HIV-1 infection1 trial

References

Drug Info

Quick Facts

Related News